Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Aravive's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ARAV is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ARAV's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ARAV underperformed the US Biotechs industry which returned 24.7% over the past year.
Return vs Market: ARAV underperformed the US Market which returned 39.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Aravive's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs Aravive, Inc.'s (NASDAQ:ARAV) Shareholder Ownership Skewed Towards Insiders?
2 months ago | Simply Wall StDid Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?
4 months ago | Simply Wall StCompanies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Is Aravive undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ARAV's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ARAV's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ARAV is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ARAV is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ARAV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ARAV is good value based on its PB Ratio (1.5x) compared to the US Biotechs industry average (3.5x).
How is Aravive forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARAV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARAV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARAV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARAV's revenue (47.5% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: ARAV's revenue (47.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ARAV's Return on Equity is forecast to be high in 3 years time
How has Aravive performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARAV is currently unprofitable.
Growing Profit Margin: ARAV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ARAV is unprofitable, but has reduced losses over the past 5 years at a rate of 26.9% per year.
Accelerating Growth: Unable to compare ARAV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARAV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: ARAV has a negative Return on Equity (-40.39%), as it is currently unprofitable.
How is Aravive's financial position?
Financial Position Analysis
Short Term Liabilities: ARAV's short term assets ($81.5M) exceed its short term liabilities ($9.1M).
Long Term Liabilities: ARAV's short term assets ($81.5M) exceed its long term liabilities ($9.4M).
Debt to Equity History and Analysis
Debt Level: ARAV is debt free.
Reducing Debt: ARAV has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARAV has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ARAV has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 19.8% each year
What is Aravive current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ARAV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARAV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARAV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARAV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ARAV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gail McIntyre (57 yo)
Dr. Gail F. McIntyre, Ph.D., CH (ASCP), DABT, serves as President, Chief Executive Officer and Director at Aravive, Inc. since April 09, 2020 and served as its Chief Scientific Officer since February 12, 2...
CEO Compensation Analysis
Compensation vs Market: Gail's total compensation ($USD1.41M) is above average for companies of similar size in the US market ($USD527.51K).
Compensation vs Earnings: Gail's compensation has increased whilst the company is unprofitable.
Experienced Management: ARAV's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: ARAV's board of directors are seasoned and experienced ( 11 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.8%.
Aravive, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Aravive, Inc.
- Ticker: ARAV
- Exchange: NasdaqGS
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$101.329m
- Shares outstanding: 20.39m
- Website: https://aravive.com
Number of Employees
- Aravive, Inc.
- River Oaks Tower
- Suite 1200
- United States
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling path...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/18 00:59|
|End of Day Share Price||2021/06/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.